Adjuvant Imatinib Prolongs RFS and OS in Patients with Resected GIST Harbouring KIT Exon 9 Mutations By Ogkologos - March 10, 2026 196 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an international retrospective cohort study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Hormone Therapy for Prostate Cancer? A Genetic Test Could Help Decide March 15, 2021 With 3 Years Minimum Follow-Up, Nivolumab Plus Ipilimumab Continues to Provide... February 9, 2022 EMA Recommends Extension of Indications for Nivolumab and Ipilimumab September 25, 2020 Breaking down changes in NHS cancer waiting times in England August 17, 2023 Load more HOT NEWS Selpercatinib Shows Durable Efficacy in RET-Altered Thyroid Cancer Cómo mi diagnóstico de cáncer a los 17 años cambió mi... New on NCI’s Websites for September 2021 Pleural Effusion Emerges as a Negative Prognostic Factor for Immune Checkpoint...
